IDH1 and acute myeloid leukemia: IDH1/2 mutation is reported to occur in 20% of patients with AML and inhibits DNA damage repair genes, conferring sensitivity of cancer cells to PARPi (Sulkowski et al., 2017; Fritz et al., 2021).